ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potentia

ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing

VH184, the first, third‑generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals